INS and Alzheimer disease: Insulin-sensitizing agents such as metformin [274] and peroxisome proliferator-activated receptor gamma (PPARγ) agonists like pioglitazone [275], have been advanced into clinical trials of AD (NCT02432287; NCT00982202).